Solid tumour vaccine - Northwest Biotherapeutics

Drug Profile

Solid tumour vaccine - Northwest Biotherapeutics

Alternative Names: DCVax®-Direct; DCVax®-Direct adjuvant cancer therapy; DCVax®-Head & Neck; DCVax®-Liver; DCVax®-Lung; DCVax®-Pancreas

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwest Biotherapeutics
  • Developer Johannes Gutenberg-University Mainz; Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 21 Sep 2016 Efficacy data from a phase I trial in Solid tumours released by Northwest Biotherapeutics
  • 02 May 2016 Efficacy data from a phase I/II trial in Solid tumours released by Northwest Biotherapeutics
  • 02 May 2016 Northwest Biotherapeutics plans three phase II trials for Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top